|Videos|August 2, 2021

Roundtable: Synthetic Control Arms and Regulatory/HTA Requirements

Author(s)Parexel

A roundtable discussing the opportunities that synthetic control arms offer for patients and product developers, and how to overcome potential barriers with the use of this burgeoning clinical trial model.


Related to this article

Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.